NasdaqCM:IMTXBiotechs
Immatics (NasdaqCM:IMTX) Quarterly Loss Of €50.5 Million Tests Bullish Growth Narratives
Immatics (NasdaqCM:IMTX) has reported its FY 2025 third quarter with total revenue of €5.2 million, basic EPS of a €0.42 loss, and net income excluding extra items showing a €50.5 million loss. This keeps the focus squarely on how far the business is from breakeven. Over recent periods, the company has seen quarterly revenue move between €18.6 million and €5.2 million, while basic EPS has ranged from a €0.38 profit to a €0.58 loss, highlighting the volatility in earnings as the pipeline...